FDA to convene advisory committee for discussions of Moderna and J&J boosters, Pfizer pediatric vaccination EUA

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee Oct. 1 announced that it will meet later this month for a pair of significant discussions on COVID-19 vaccines. The committee Oct. 14 and 15 will consider the use of COVID-19 vaccine booster doses for Moderna and Johnson & Johnson, including a discussion on “mix and match” booster regimens of any of the three authorized or approved vaccines. Then, on Oct. 26, the committee will consider an expected request by Pfizer to allow its vaccine’s use for children age 5 through 11. Pfizer in late September submitted data in support of amending its emergency use authorization to include this pediatric group, though it has yet to formally request the change.